Benzinga | May 19, 2021 08:06AM EDT

BeiGene's Brukinsa US Application For Expanded Use Under FDA Review

* The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL) and granted priority review.

* The application covers adult MZL patients who have received at least one prior anti-CD20-based therapy.

* The agency's target action date is September 19.

* Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase to treat various B-cell malignancies.

* Price Action: BGNE shares closed at $337.98 on Tuesday.